Home / Resource Library / Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma

Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma

Results of a phase II trial of everolimus in treating relpased Follicular lymphoma.